Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

Completed · Phase 3

Conditions studied: Atrial Fibrillation, Atrial Flutter

In brief

The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.

Key facts

Study ID
NCT00412984
Run by
Bristol-Myers Squibb
People needed
20976
Starts
2006-12-31
Expected to finish
2011-05-25
Last updated by the study team
2018-07-03

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.